Trial Profile

A Phase III HEEALING 1 study of linaprazan glurate in patients with Erosive Gastroesophageal Reflux Disease (GERD).

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 30 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Linaprazan-glurate (Primary)
Indications Gastro-oesophageal reflux
Focus Registrational; Therapeutic Use
Acronyms HEEALING 1

Most Recent Events

30 Oct 2025 New trial record
12 Sep 2025 According to the Cinclus Pharma Media Release, the trial will enroll approx. 500 patients across up to 100 clinical sites in seven European countries.
12 Sep 2025 According to the Cinclus Pharma Media Release, the company announced the screening of the first patient with erosive gastroesophageal reflux disease (GERD) in its Phase III clinical trial of linaprazan glurate.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com